Patents by Inventor Julian A. Kim

Julian A. Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230013585
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: May 27, 2021
    Publication date: January 19, 2023
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Publication number: 20220213091
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Application
    Filed: November 9, 2021
    Publication date: July 7, 2022
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Patent number: 11071754
    Abstract: A method of treating cancer in a subject includes contacting an enriched population of T-cells obtained from cancer or tumor draining lymph nodes ex-vivo with: an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and optionally a VEGF inhibitor and/or an IL-2 receptor agonist, at amounts effective to activate and expand the T-cells and administering the activated and expanded T-cells to the subject.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: July 27, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Julian Kim, Kevin Choong, Hallie Graor, Mei Zhang, John Ammori, Anthony Visioni
  • Publication number: 20210196745
    Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.
    Type: Application
    Filed: February 10, 2021
    Publication date: July 1, 2021
    Inventors: Mei Zhang, Alex Y. Huang, Julian Kim
  • Patent number: 10946038
    Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: March 16, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mei Zhang, Alex Y. Huang, Julian Kim
  • Publication number: 20190046557
    Abstract: A method of treating a subject having cancer is described that includes administering a therapeutically effective amount of a ?-(1,3)-(1,4) glucan to the subject. Methods of immunostimulating in a subject by administering an effective amount of a ?-(1,3)-(1,4) glucan to the subject are also described.
    Type: Application
    Filed: August 9, 2018
    Publication date: February 14, 2019
    Inventors: Mei Zhang, Alex Y. Huang, Julian Kim
  • Publication number: 20180228844
    Abstract: A method of treating cancer in a subject includes contacting an enriched population of T-cells obtained from cancer or tumor draining lymph nodes ex-vivo with: an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and optionally a VEGF inhibitor and/or an IL-2 receptor agonist, at amounts effective to activate and expand the T-cells and administering the activated and expanded T-cells to the subject.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 16, 2018
    Inventors: Julian Kim, Kevin Choong, Hallie Graor, Mei Zhang, John Ammori, Anthony Visioni
  • Patent number: 9944898
    Abstract: A method for the expansion of tumor-specific T-cells includes obtaining an enriched population of T-cells from a subject with cancer; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, to activate and expand the T-cells.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 17, 2018
    Assignee: Case Western Reserve University
    Inventors: Julian Kim, Hallie Graor, Mei Zhang, Anthony Visioni
  • Publication number: 20140255368
    Abstract: A method for the expansion of tumor-specific T-cells includes obtaining an enriched population of T-cells from a subject with cancer; and contacting the enriched population of T-cells ex-vivo with: (i) an anti-CD3 antibody, an anti-CD28 antibody, and/or functional fragments thereof, and (ii) a VEGF inhibitor, to activate and expand the T-cells.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 11, 2014
    Inventors: Julian Kim, Hallie Graor, Mei Zhang, Anthony Visioni
  • Publication number: 20090170197
    Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nucleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.
    Type: Application
    Filed: July 9, 2008
    Publication date: July 2, 2009
    Applicant: SIRNA THERAPEUTICS INC.
    Inventors: Pamela Pavco, James McSwiggen, Dan Stinchcomb, Jaime Escobedo, Julian Kim, Daniel Lindner
  • Publication number: 20040102389
    Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nuleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.
    Type: Application
    Filed: November 4, 2002
    Publication date: May 27, 2004
    Applicant: Ribozyme Pharmaceuticals, Inc.
    Inventors: Pamela Pavco, James McSwiggen, Dan Stinchcomb, Jaime Escobedo, Julian Kim, Daniel Lindner
  • Patent number: 6093381
    Abstract: Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the patient is administered mitogenically stimulated lymph node lymphocytes or the supernatant therefrom. The lymph node lymphocytes are patient excised lymph node lymphocytes enriched in tumor reactive cells, such as CD4+ tumor reactive cells. Radiolabeled locators (e.g., antibodies) can be used along with a portable radiation detector to intraoperatively determine which lymph nodes bear lymph node lymphocytes enriched in tumor reactive cells. The patient excised lymph node lymphocytes enriched in tumor reactive cells then are subjected to mitogenic stimulation for their expansion and administration to the patient.
    Type: Grant
    Filed: December 10, 1997
    Date of Patent: July 25, 2000
    Assignee: Neoprobe Corporation
    Inventors: Pierre L. Triozzi, Julian A. Kim
  • Patent number: 5814295
    Abstract: The present invention is directed to a method for reliably determining lymph nodes enriched in tumor reactive cells, e.g., CD4+tumor-specific lymphocytes. This method includes the steps of administering to a patient an effective amount of a radiolabeled locator which specifically binds a marker produced by or associated with neoplastic tissue. Time is permitted to elapse following the administration for the radiolabeled locator to preferentially concentrate in any neoplastic tissue and for unbound radiolabeled locator to be cleared, so as to increase the ratio of photon emissions from neoplastic tissue to background photon emissions in the patient. After the time has elapsed, the patient is accessed with a radiation detection probe for determining lymph node sites exhibiting accretion of the radiolabeled locator by detecting with the probe elevated levels of radiation at the lymph node sites.
    Type: Grant
    Filed: July 13, 1994
    Date of Patent: September 29, 1998
    Assignee: The Ohio State University Research Foundation
    Inventors: Edward W. Martin, Jr., Brian J. Czerniecki, Pierre L. Triozzi, Julian A. Kim